Overview

This bill amends the Human Fertilisation and Embryology Act 1990 to improve the welfare of women undergoing fertility treatment. It mandates the collection, anonymization, and annual publication of data on drug dosages, live birth rates per embryo transferred, and adverse health outcomes for women and children resulting from treatment.

Description

The bill modifies Section 13 of the 1990 Act, adding requirements for fertility treatment licenses. Specifically:

• Drug Dosages and Live Birth Rates: Licenses must now specify the drugs and dosages used, and the live birth rate per embryo transferred.
• Adverse Health Outcomes: Data on adverse health outcomes for both women and children (including low birth weight and prematurity) must be collected.
• Data Collection and Publication: The Human Fertilisation and Embryology Authority (HFEA) is required to collect, anonymize, and publish this data annually.
• Welfare Focus: The existing wording regarding patient welfare is amended to explicitly include the "welfare of the woman and" in the bill's text.

The bill applies to England, Wales, Scotland, and Northern Ireland and comes into force immediately upon passage.

Government Spending

The bill does not directly specify any government spending figures. However, the implementation will likely incur costs associated with data collection, anonymization, and publication by the HFEA.

Groups Affected

The bill primarily affects:

• Women undergoing fertility treatment: The bill aims to improve their welfare by increasing transparency and monitoring of treatment.
• Fertility clinics: Clinics will need to comply with the new data collection and reporting requirements.
• The Human Fertilisation and Embryology Authority (HFEA): The HFEA will be responsible for the collection, anonymization, and publication of the data.
• Researchers and policymakers: The published data will provide valuable information for research into fertility treatment and policy development.

Powered by nyModel